Before you disclose, you are either testing or exposed.
The IRomics SIA™ provides management with a structured investor-read assessment before disclosure.
Investor Relations, Quantified.
The Asymmetry Problem
Your disclosures are now being evaluated on two analytical planes: human and machine.
Institutional investors increasingly use AI to evaluate disclosures before investment decisions are made. Most management teams still rely primarily on traditional human review before releasing market-moving disclosures.
That’s the asymmetry.
The question is no longer whether your disclosure will be analyzed. The question is whether management sees the same risks, assumptions, and conclusions an AI-informed market may see.
The IRomics Sentiment Intelligence Agent (SIA™) helps close that gap by providing management with a structured investor-read assessment before the disclosure reaches the market.
Close the gap before you disclose.
The
IRomics
SIA
The IRomics Difference
Not General AI. Biopharma AI.
Most AI tools bring general intelligence to a specialized problem. The IRomics SIA brings specialized intelligence designed specifically for biopharma investor relations.
Built specifically for biopharma investor relations, including:
- Clinical and development context
- Regulatory context
- Company disclosure history
- Competitive positioning
- Investor response patterns
Why Specialization Matters
General AI processes your content.
The IRomics SIA understands the implications.
The SIA applies specialized AI, purpose-built for biopharma investor relations, across multiple investor-relevant analytical lenses. The result is a structured investor-read assessment before disclosure, helping management understand not only what a disclosure says, but how it is likely to be interpreted by today’s AI-informed market.
SIA Analysis Framework
The IRomics SIA evaluates each disclosure through multiple investor-relevant analytical lenses before producing its structured investor-read assessment.
The SIA runs inside an encrypted, access-controlled environment — your MNPI is never used to train outside models and never shared externally. Client data stays separated, never co-mingled with another client's for inference or training.
The
Market
Don’t Be Exposed
The Market Has No Rewind
The IRomics SIA does. Every disclosure is a high-stakes interpretation event: a data readout, earnings call, press release, or investor day where getting it wrong isn’t an option. Once it’s public, you can’t take it back.
The IRomics SIA gives you the rewind before release: an investor-read assessment across both analytical planes, human and machine, with enough time to refine, align, and get it right before the market sees it.
The New “OMICS”
Genomics: maps your genetic code.
Proteomics: profiles your proteins.
Metabolomics: charts your chemistry.
IRomics: models your investor narrative.
Your story.
Your communications.
Your stakeholders.
Lexicon
IRomics™ noun / eye-ARE-oh-miks
The data-driven study and optimization of investor relations at the molecular level of messaging.
Application: Used by companies to quantify, evaluate, and refine communications to improve clarity, consistency, and impact.
Who
IRomics
Serves
Who We Serve
IR Teams
The SIA provides a structured framework to improve disclosure quality across communication events, including earnings releases, data readouts, investor days, and pipeline updates, while identifying potential interpretation risks before investors see the communication.
IR Agencies and Advisors
IRomics is designed to work alongside agency counsel, serving as the analytical layer that quantifies and pressure-tests the communications strategy you are already providing your clients.
As AI increasingly mediates how investors interpret disclosures, advisors who can anticipate that interpretation will counsel at a different level than those who can’t. IRomics gives your team the framework to do that systematically.
Connect
Disclose with Confidence.
Know what investors may see before you release.
Optimize before you disclose.
Request a meeting to learn more about IRomics: signal@IRomics.com